1 / 21

Rian Groen 1-2 , Marrit de Boer 3 , Marte Swart 2-5 , Rikus Knegtering 2-4-5

Sex & drugs Sexual dysfunctions in patients with schizophrenia using depot antipsychotics: a cross-sectional study. Rian Groen 1-2 , Marrit de Boer 3 , Marte Swart 2-5 , Rikus Knegtering 2-4-5

tuan
Download Presentation

Rian Groen 1-2 , Marrit de Boer 3 , Marte Swart 2-5 , Rikus Knegtering 2-4-5

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Sex & drugsSexual dysfunctions in patients with schizophrenia using depot antipsychotics: a cross-sectional study Rian Groen1-2, Marrit de Boer3, Marte Swart2-5, Rikus Knegtering2-4-5 Lentis Center for Mental Health Care Groningen, 1Linis FACT Winschoten and 2Lentis Research Center. University of Groningen, University Medical Center Groningen, 3Department of Psychiatry, 4Neuroimaging center and 5 Rob Giel Research, The Netherlands

  2. Content • Background • Practice • The aim • Expectation • Research population • Methods • Demografics • Results • Discussion • Conclusions

  3. Background • Sexual dysfunctions (SD) are frequently occuring side effects of oral antipsychotic medication (30-60%). • Negative effects on self-image, compliance and the quality of life. • SD related to long-acting injectable (depot) antipsychotics are infrequently studied.

  4. Practice • Very common • Ask • Difficult • Not much research

  5. The aim To compare the frequency and types of SD in patients using long-acting risperidone and paliperidone (group A) with patients using long-acting first-generation antipsychotics (group B).

  6. Expectation • More SD expected in Risperidone en Paliperidone than First-generation antipsychotics • Rising prolactin levels • Higher dosages necessary for antipsychotic effect. • Paliperidone metabolite Risperidone.

  7. “I stopped taking the medicine because I prefer the original disease to the side effects.”

  8. Research Population • Lentis / Groningen/ Winschoten. • 38 outpatients • Psychotic disorder • Receiving treatment from Assertive Community Treatment teams • Aged 18-60 • Using depot antipsychotics

  9. Methods • Divided into 2 groups: • Group A; risperidone and paliperidone • Group B; long-acting first-generation antipsychotics. Haloperidol, zuclopentixol, fluphenazine, broomperidol, flupentixol.

  10. Methods • Informing patients • On the day of depot injection. • The Antipsychotics and Sexual Functioning Questionnaire (ASFQ), a semistructured interview. • libido, orgasm, erection, ejaculation, lubrication, galactorrhea, gynaecomastia and pain.

  11. Demographics (1)

  12. Demographics (2) • Next to depot oral psychotropic drugs -7 people (58,3 %) of group A. -18 people (69,2 %) of group B. • Most common was clozapine • Comedication • 6 people (50 %) - 16 people (61 %) • Most common co-medication - Antidiabetic and Anticholinergic(group A) - Protonpump inhibitors group B)

  13. Results

  14. Different SD per depot-group shown in percentages. NB; Group A; risperidone en paliperidone and group B; first generation antipsycotics.

  15. Discussion • Challenging research population • Small sample size • Oral psychotropic drugs • Co-medication

  16. Conclusions • No significant difference • Frequently reported • Almost half of the population • Further research is necessary. • Ask specifically about sexual side effects. • Discuss side effects openly • Consider them in the course of treatment. • Treatment alternatives

  17. Questions? Rian Groen GGZ VS i.o. e-mail: ag.groen@lentis.nl

  18. Demografische gegevens (2)

More Related